THERIVA BIOLOGICS INC Stock Price, News & Analysis

Theriva Biologics (NYSE: TOVX) reported Q3 2025 operational and financial results with key clinical updates and cash guidance. Expanded VIRAGE Phase 2b data for VCN-01 in metastatic PDAC showed the study met primary endpoints with improved OS, PFS and DoR, measurable viral genomes for ≥3 months, and greater benefit with two doses.

Preclinical data for next‑gen VCN-12 showed higher tumor killing and hyaluronidase activity versus VCN-01. Cash was $7.5M at Sept 30, 2025 and increased to $15.5M by Nov 10, 2025, funding operations into Q1 2027.

Theriva Biologics (NYSE American: TOVX) announced awareness of unusual trading activity in its common stock on the NYSE American on October 24, 2025. The company said it has made inquiries, does not believe corrective actions are appropriate, and is not aware of any material development in its business or affairs that would explain the trading.

The company noted a prior announcement on October 13, 2025 about presenting expanded data from the VIRAGE trial of VCN-01 at a mini oral session during ESMO 2025.

Theriva Biologics (NYSE American: TOVX) entered a warrant inducement agreement to accelerate the exercise of existing warrants for up to 7,360,460 shares at a reduced price of $0.54 per share, generating approximately $4.0 million in gross proceeds, with an offer window to raise up to an additional $0.4 million. In return, investors will receive new unregistered warrants to purchase up to 14,720,920 shares at $0.54, exercisable after stockholder approval and expiring five years after the Approval Date. Closing is expected on or about October 17, 2025. Net proceeds are intended for working capital and general corporate purposes. A.G.P./Alliance Global Partners acted as exclusive financial advisor.

Theriva Biologics (NYSE American: TOVX) announced two upcoming medical meeting presentations on October 20, 2025. VCN-01 expanded data from the VIRAGE Phase 2b trial in metastatic pancreatic cancer (mPDAC) will be presented as a mini-oral at ESMO 2025 by Dr. Rocío Garcia-Carbonero (Abstract #2216MO) at 09:28 a.m. CEST in Bonn Auditorium, Messe Berlin.

SYN-004 blinded safety and PK data from the Phase 1b/2a randomized, double-blinded, placebo-controlled trial in allogeneic HCT recipients will be presented as a poster at IDWeek 2025 by Dr. Erik R. Dubberke (Abstract #P-104) on October 20, 2025 from 12:15–1:30 p.m. EDT in Poster Hall B4-5, Georgia World Congress Center, Atlanta.

Theriva Biologics (NYSE American: TOVX) will present preclinical data for VCN-12, a next‑generation oncolytic adenovirus from the VCN‑X discovery program, at the 32nd Annual ESGCT meeting in Seville on Oct 8, 2025 at 08:30 CEST.

Presenter Dr. Ramón Alemany will describe mechanistic data showing VCN‑12 is derived from clinical lead VCN‑01 and is armed with additional transgenes intended to improve tumor cell lysis, stroma degradation, and antitumor immunity. A pre‑ESGCT monograph also reports preclinical intracranial administration data for VCN‑01 supporting further development for brain tumors.

Theriva Biologics (NYSE American: TOVX) reported significant progress in Q2 2025, highlighted by positive topline results from their VIRAGE Phase 2b trial of VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic cancer. The drug, combined with standard chemotherapy, demonstrated improved overall survival, progression-free survival, and duration of response.

The company also presented Phase 1 safety and clinical outcome data for VCN-01 in retinoblastoma at ASCO 2025. Financially, Theriva reported $12.1 million in cash as of June 30, 2025, with runway extending into Q1 2026. General and administrative expenses increased significantly to $11.2 million, while R&D expenses decreased 34% to $2.0 million.

Theriva Biologics (NYSE: TOVX) announced two key developments for their VCN-01 (zabilugene almadenorepvec) therapy. First, data from a Phase 1 clinical trial evaluating VCN-01 in refractory retinoblastoma patients will be presented at the ASCO Annual Meeting on May 31st, 2025. The study, conducted at Sant Joan de Déu Barcelona Children's Hospital, assessed safety and tolerability in patients who were unresponsive to conventional treatments. Early indicators suggest positive results, with investigators noting a tolerable toxicity profile and encouraging response in refractory vitreous seeds. Additionally, Theriva management will participate in an off-site meeting during ASCO to review topline results from the VIRAGE Phase 2b trial of VCN-01 in first-line metastatic pancreatic ductal adenocarcinoma (PDAC), focusing on insights for a potential Phase 3 trial design.

Theriva Biologics (NYSE: TOVX) reported significant progress in Q1 2025, highlighted by positive results from the VIRAGE Phase 2b trial of VCN-01 for pancreatic cancer. The trial met primary efficacy and safety endpoints, showing increased overall survival when combined with standard chemotherapy. The company recently completed a public offering raising $7.5 million, extending cash runway into Q1 2026. Financial results show decreased expenses with G&A down 25% to $1.4M and R&D down 14% to $3.0M. Post-offering cash position stands at $14.1 million. The company plans to scale up VCN-01 manufacturing and design a Phase 3 trial for metastatic pancreatic ductal adenocarcinoma (mPDAC). Additionally, data from SYN-004's Phase 1b/2a trial for preventing acute graft-versus-host-disease was presented at ESCMID Global.

Theriva Biologics (NYSE American: TOVX) has completed its previously announced public offering, raising $7.5 million in gross proceeds. The offering consisted of 6,818,180 shares of common stock (or pre-funded warrants) and warrants to purchase an equal number of shares at a combined price of $1.10 per share and accompanying warrant.

The warrants are immediately exercisable at $1.10 per share and will expire in five years. The company plans to use the proceeds for working capital, general corporate purposes, research and development, and manufacturing scale-up. A.G.P./Alliance Global Partners served as the sole placement agent for the offering.